Clinical Ink, a Philadelphia, PA and Winston-Salem, NC-based provider of eSource solutions for clinical trials, raised $4.3m Series B funding.
The round was led by FCA Venture Partners. In conjunction with the funding, Matthew King, Managing Partner of FCA Venture Partners, joined Clinical Ink’s Board of Directors.
The company intends to use the funds to build to expand the management team, and development capabilities.
Led by Ed Seguine, CEO, Clinical Ink provides an eSource platform, SureSource, which replaces paper source documents and CRFs by capturing clinical trial data during the subject visit on a tablet PC.